Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2061

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2061
---
 capitalists or pharmaceutical companies. There
is a growing yet still small number of accelerator programs and incubators aiming to bridge the bench-to-bedside gap at specific institutions;
however, the gap remains wide and we believe this presents an attractive opportunity for us to become an industry leader by addressing
a need to accelerate the advancement of therapeutics that can address significant unmet medical needs.

The
core elements that we believe differentiate our business model include:

    ●
    Harnessing
    inventions and technologies from research universities and medical centers. We search for opportunities wherever they can be found,
    and we believe “hidden gems” can be uncovered by our team. We are experienced at identifying and sourcing breakthrough
    discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.
    We know how to assess and test their scientific merits and commercial relevance, and we have extensive experience working with these
    institutions and licensing their assets. For example, our leadership team has evaluated thousands of innovations, taken multiple
    products through IND filings and into clinical development, and been involved in the launch of 8 biotech companies.

    ●
    Developing
    new drug therapies through an operationally efficient, evidence-based and milestone-driven approach. Once we select an asset for
    development, we pursue what we believe are appropriate development strategies that we aim to execute efficiently by leveraging contract
    research and contract manufacturing organizations, or CROs and CMOs, respectively, and other drug development experts and consultants.
    We aim to rapidly and efficiently advance our product candidates to objective critical decision points. We direct resources toward
    the opportunities that we believe are the most promising, and we discontinue programs that do not meet our performance thresholds.
    We are skilled at objectively directing internal resources, and at leveraging external resources (such as CROs and CMOs), in order
    to progress product candidates in accordance with well-defined criteria for advancement within a lean cost structure.

    ●
    Building
    a diverse portfolio of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly
    by program progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel. Our success is
    not dependent on any one particular program, disease area or indication, which mitigates business risk, and allows us the flexibility
    to opportunistically develop product candidates, regardless of therapeutic area. We believe that this model ensures that we remain
    focused on assets with the most